+55%

est. 2Y upside i

HealthcareSeries C

Nourish is addressing the root cause of the chronic disease crisis through AI-powered, insurance-covered virtual nutrition care. We are tackling one of the most important problems in the world — our broken healthcare system. We are building a healthcare system that is patient-friendly, prioritizes lifestyle change, delivers outcomes, and lowers costs.

Rank

#884

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Low

Nourish offers a moderately attractive equity upside with a probability-weighted expected return of ~55% over 2 years, but low confidence due to unavailable revenue data.

Last updated: July 19, 2026

Bull (35%)+100%

Nourish maintains momentum as the leading AI-native metabolic health clinic, expanding insurance partnerships and achieving 2x valuation to $3.5B within 2 years, driven by continued GLP-1 drug adoption and network effects.

Base (50%)+50%

Nourish grows steadily with a 50% valuation increase to $2.625B, reflecting competitive market dynamics and moderate revenue growth, as it consolidates its position in the metabolic health space.

Bear (15%)-30%

Intensified competition from Omada, Noom, and Calibrate, combined with slower insurance reimbursement growth, compresses valuation by 30% to $1.225B, still well above preference stack.

Est. time to liquidity~2.0 years

Preference Stack Risk

moderate

Funding Intensity

1229%

Total preference of $215M vs. $1.75B valuation = 12.3% overhang, manageable but non-trivial in downside scenarios.

Dilution Risk

low

Company is profitable and just raised $100M; unlikely to need additional capital within 2 years, so minimal dilution expected.

Secondary Liquidity

none

No secondary market activity reported; liquidity likely tied to a future IPO or acquisition.

Other — 1 role

View all 1 open roles at Nourish →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Nourish's data — designed to show you've done your homework.

  • 1

    “How does Nourish differentiate from Omada and Noom in terms of long-term patient outcomes and cost savings for insurers?”

  • 2

    “What are the key drivers of revenue growth beyond insurance contracts, and what is the path to doubling ARR?”

  • 3

    “Given the recent $100M raise, what is the expected timeline to an IPO or secondary liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates +55% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.